Induction of inosine monophosphate dehydrogenase activity after long- term treatment with mycophenolate mofetil

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 6, 1999, Pages 640-648

  Sanquer, Sylvia ^a,b,c   Breil, Myriam ^a,b   Baron, Christophe ^a,b   Dhamane, Djamal ^a,b   Astier, Alain ^a,b   Lang, Philippe ^a,b  

^a Unit UPRESS B JE 2129 on Organ T   (France)

^b Department Hematology Physiology   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HYPOXANTHINE; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; HUMAN; HUMAN CELL; KIDNEY TRANSPLANTATION; LONG TERM CARE; LYMPHOCYTE PROLIFERATION; MITOGENESIS; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; ENZYME INDUCTION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0033047817     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)90085-1     Document Type: Article

References (22)

1. 1. Allison AC, Kowalski WJ, Muller CD, Eugui EM. Mechanism of action of mycophenolic acid. Ann NY Acad Sci 1993;696:63-87.
2. 2. Young CJ, Sollinger HW. RS-61443: a new immunosuppressive agent. Transplant Proc 1994;26:3144-6.
3. 3. Allison AC, Eugui E. Mycophenolate mofetil, a rationally designed immunosuppressive drug. Clin Transplant 1993; 7:96-112.
4. 4. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995;60:225-32.
5. 5. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticoids for prevention of acute rejection. Lancet 1995;345:1321-5.
6. 6. The International Mycophenolate Mofetil Study Group. A long-term randomized multicenter study of mycophenolate mofetil (MMF) in cadaveric renal transplantation: results at 3 years. Sixteenth Annual Meeting of American Society of Transplant Physicians, Chicago, Illinois, May 12-19, 1997.
7. 7. Sanquer S, Breil M, Baron C, Dahmane D, Astier A, Lang P. Trough blood concentrations in long-term treatment with mycophenolate mofetil. Lancet 1998;351:1557.
8. 8. Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 1996;62:666-72.
9. 9. Haley CJ, Jaklitsch A, McGowan B. Feasibility of an EMIT assay for mycophenolic acid in plasma [abstract]. Ther Drug Monit 1995;17:431.
10. 10. Holt DW, Johnston A. Monitoring new immunosuppressive agents: Are the methods adequate? Drug Metabol Drug Interact 1997;14:5-15.
11. 11. Balzarini J, De Clereq E. Assay method for monitoring the inhibitory effects of antimetabolites on the activity of inosinate dehydrogenase in intact human CEM lymphocytes. Biochem J 1992;287:785-90.
12. 12. Langman LJ, LeGarr DF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity. Clin Chem 1995;41:295-9.
13. 13. Langman LJ, Nakakura H, Thliveris JA, LeGatt DF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid in rabbit heterotopic heart transplant model. Ther Drug Monit 1997;19:146-52.
14. 14. Bullingham RES, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS611443): a short review. Transplant Proc 1996;28:925-9.
15. 15. Blackley RL. Nucleotides. In: Zubay G, editor. Biochemistry. Macmillan; 1993. p. 806-46.
16. 16. Natsumeda Y, Carr SF. Human type I and II IMP dehydrogenases as drug targets. Ann NY Acad Sci 1993;696:88-93.
17. 17. Konno Y, Natsumeda Y, Nagai M, Yamaji Y, Ohno S, Suzuki K, et al. Expression of human IMP dehydrogenase types I and II in Escherichia coli and distribution in human normal lymphocytes and leukemic cell lines. J Biol Chem 1991;266:506-9.
18. 18. Nagai M, Natsumeda Y, Konno Y, Hoffman R, Irino S, Weber G. Selective up-regulation of type II inosine 5′-monophosphate dehydrogenase messenger RNA expression in human leukemias. Cancer Res 1991;51:3886-90.
19. 19. Collart FR, Chubb CB, Mirkin BL, Huberman E. Increased inosinc-5′-monophosphate dehydrogenase gene expression in solid tumor tissues and tumor cell lines. Cancer Res 1992;52:5826-8.
20. 20. Dayton JS, Lindsten T, Thompson CB, Mitchell BS. Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. J Immunol 1994;142:984-91.
21. 21. Morrow CS, Cowan KH. Antineoplastic drug resistance and breast cancer. Ann NY Acad Sci 1993;698:289-312.
22. 22. Curt GA, Carney DN, Cowan KH, Jolivet J. Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N Eng] J Med 1983;308:199-202.